Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

As an over-expressed flavoprotein in several kinds of tumor cells, NAD(P)H: quinone oxidoreductase-1 (NQO1) is considered as a potent biomarker in early-stage cancer diagnosis. Developing a fast, selective and sensitive method of monitoring NQO1 on cellular level will greatly promote cancer diagnosis in clinical practice. In this paper, a fast NQO1 responsive fluorescence probe SYZ-30 containing quinone acid and 7-nitro-2,1,3-benzoxadiazole (NBD) fluorophore is constructed. The probe could selectively respond to NQO1 and rapidly emit strong fluorescence in vitro within only 5 min. Notably, the peak fluorescent intensities at 550 nm showed a linear relationship with NQO1 concentrations in the range of 3-30 ng/ml and limit of detection (LOD) was 0.0667 ng/ml. Furthermore, it was validated that the probe has good biocompatibility and could be applied for bio-imaging in NQO1 over-expressed cancer cells, together with its mitochondria targeting ability. Importantly, confocal fluorescence imaging confirmed the NQO1 detection ability on cellular level, which can be used for real-time detection of several cancer subtypes like adenocarcinoma. To conclude, the probe is rapidly responsive, highly sensitive and selective which will potentially become a practical tool for early cancer detection and diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.talanta.2019.02.009DOI Listing

Publication Analysis

Top Keywords

cancer diagnosis
12
nqo1
8
nqo1 responsive
8
responsive fluorescence
8
fluorescence probe
8
cellular level
8
cancer
6
probe
5
design synthesis
4
synthesis nqo1
4

Similar Publications

Importance: Increasingly, strategies to systematically detect melanomas invoke targeted approaches, whereby those at highest risk are prioritized for skin screening. Many tools exist to predict future melanoma risk, but most have limited accuracy and are potentially biased.

Objectives: To develop an improved melanoma risk prediction tool for invasive melanoma.

View Article and Find Full Text PDF

Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.

View Article and Find Full Text PDF

Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.

JAMA Netw Open

September 2025

Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.

Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.

Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).

Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.

View Article and Find Full Text PDF

Importance: Merkel cell carcinoma (MCC) is typically caused by the Merkel cell polyomavirus (MCPyV) and recurs in 40% of patients. Half of patients with MCC produce antibodies to MCPyV oncoproteins, the titers of which rise with disease recurrence and fall after successful treatment.

Objective: To assess the utility of MCPyV oncoprotein antibodies for early detection of first recurrence of MCC in a real-world clinical setting.

View Article and Find Full Text PDF

Background: Ovarian cancer remains the most lethal gynecological cancer, with fewer than 50% of patients surviving more than five years after diagnosis. This study aimed to analyze the global epidemiological trends of ovarian cancer from 1990 to 2021 and also project its prevalence to 2050, providing insights into these evolving patterns and helping health policymakers use healthcare resources more effectively.

Methods: This study comprehensively analyzes the original data related to ovarian cancer from the GBD 2021 database, employing a variety of methods including descriptive analysis, correlation analysis, age-period-cohort (APC) analysis, decomposition analysis, predictive analysis, frontier analysis, and health inequality analysis.

View Article and Find Full Text PDF